Emerging Markets Regulatory Tracker: Brazil, China (Vol. 4 No. 20)
This article was originally published in PharmAsia News
Brazil’s Senate seeks an increase in clinical drug trials while Abbott Laboratires voluntarily recalls a blood glucose meter in China on concerns of possible erroneous results.
You may also be interested in...
India’s health ministry has laid out basic steps towards an overhaul of drug regulation at the local level, identifying a number of areas of concern.
China has released the results of back on proposed standards for the accreditation of clinical trial committees, investigators and sites.
China has finalized revised rules for the classification of medical devices, which will come into effect from the start of next year.